- Home
- INDO vs KPTI Comparison
INDO vs KPTI Comparison
Compare INDO & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDO
- KPTI
- Stock Information
- Founded
- INDO 2018
- KPTI 2008
- Country
- INDO Indonesia
- KPTI United States
- Employees
- INDO N/A
- KPTI N/A
- Industry
- INDO Oil & Gas Production
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- INDO Energy
- KPTI Health Care
- Exchange
- INDO Nasdaq
- KPTI Nasdaq
- Market Cap
- INDO 45.6M
- KPTI 44.5M
- IPO Year
- INDO 2019
- KPTI 2013
- Fundamental
- Price
- INDO $3.08
- KPTI $5.90
- Analyst Decision
- INDO
- KPTI Buy
- Analyst Count
- INDO 0
- KPTI 6
- Target Price
- INDO N/A
- KPTI $39.80
- AVG Volume (30 Days)
- INDO 412.2K
- KPTI 242.6K
- Earning Date
- INDO 10-24-2025
- KPTI 11-04-2025
- Dividend Yield
- INDO N/A
- KPTI N/A
- EPS Growth
- INDO N/A
- KPTI N/A
- EPS
- INDO N/A
- KPTI N/A
- Revenue
- INDO $2,293,625.00
- KPTI $137,269,000.00
- Revenue This Year
- INDO N/A
- KPTI $3.40
- Revenue Next Year
- INDO N/A
- KPTI $9.69
- P/E Ratio
- INDO N/A
- KPTI N/A
- Revenue Growth
- INDO N/A
- KPTI N/A
- 52 Week Low
- INDO $2.10
- KPTI $3.51
- 52 Week High
- INDO $7.95
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- INDO 52.38
- KPTI 33.94
- Support Level
- INDO $2.94
- KPTI $6.08
- Resistance Level
- INDO $3.06
- KPTI $6.68
- Average True Range (ATR)
- INDO 0.13
- KPTI 0.64
- MACD
- INDO 0.00
- KPTI -0.19
- Stochastic Oscillator
- INDO 35.85
- KPTI 2.95
About INDO Indonesia Energy Corporation Limited
Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. The company is an independent energy company engaged in the oil and gas business and holds two oil and gas assets through its subsidiaries in Indonesia: The Kruh Block and the Citarum Block. It has also identified a potential third exploration block known as the Rangkas area. . Its portfolio consists of Kruh Block and Citarum Block. The company generates its revenue from oil and gas sales.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.